DOI QR코드

DOI QR Code

Bicluster and Pathway Enrichment Analysis of HCV-induced Cirrhosis and Hepatocellular Carcinoma

  • Cheng, Peng (Department of Oncology, PLA general hospital of Chengdu Commond, Clinical Medical College of The Third Medical Military University) ;
  • Cheng, You (Department of Otolaryngology-Head and Neck Surgery, PLA General Hospital of Nanjing Commond, Clinical Medical College of Nanjing University) ;
  • Su, Mei X. (Department of Oncology, PLA general hospital of Chengdu Commond, Clinical Medical College of The Third Medical Military University) ;
  • Li, Dong (Department of Oncology, PLA general hospital of Chengdu Commond, Clinical Medical College of The Third Medical Military University) ;
  • Zhao, Guo Z. (Department of Oncology, PLA general hospital of Chengdu Commond, Clinical Medical College of The Third Medical Military University) ;
  • Gao, Hui (Department of Oncology, PLA general hospital of Chengdu Commond, Clinical Medical College of The Third Medical Military University) ;
  • Li, Yan (Department of Oncology, PLA general hospital of Chengdu Commond, Clinical Medical College of The Third Medical Military University) ;
  • Zhu, Jie Y. (Department of Oncology, PLA general hospital of Chengdu Commond, Clinical Medical College of The Third Medical Military University) ;
  • Li, Hua (Department of Oncology, PLA general hospital of Chengdu Commond, Clinical Medical College of The Third Medical Military University) ;
  • Zhang, Tao (Department of Oncology, PLA general hospital of Chengdu Commond, Clinical Medical College of The Third Medical Military University)
  • Published : 2012.08.31

Abstract

Background: Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the most common form of liver cancer. However, while it is associated frequently with hepatitis C virus (HCV) there is only an elementary understanding of its molecular pathogenesis. Methods: To gain insight into the molecular mechanisms of HCV-induced hepatocarcinogenesis, we performed microarray analysis on 75 surgical liver samples from 48 HCV-infected patients. Results: There were 395 differentially expressed geness between cirrhotic samples and HCC samples. Of these, 125 genes were up-regulated and 270 genes were down-regulated. We performed pathway enrichment analysis and screened as described previously. Conclusions: The differentially expressed genes might be involved in hepatocarcinogenesis through upregulating the pathways of ECM-receptor interaction, focal adhesion, cell adhesion molecules and other cancer-related pathways, and downregulating the pathways of "complement and coagulation cascades". We hope our results could aid in seeking of therapeutic targets for HCV-induced hepatocellular carcinoma.

Keywords

Bicluster analysis;pathway enrichment;cirrhosis;hepatocellular carcinoma

References

  1. Abedi-Ardekani B, Gouas D, Villar S, et al (2011). TP53 Mutations and HBX Status Analysis in Hepatocellular Carcinomas from Iran: Evidence for Lack of Association between HBV Genotype D and TP53 R249S Mutations. Hepat Res Treat, 2011, 475965.
  2. Amitrano L, Guardascione MA, Brancaccio V, Balzano A (2002). Coagulation disorders in liver disease. Semin Liver Dis, 22, 83-96. https://doi.org/10.1055/s-2002-23205
  3. Avila MA, Berasain C, Sangro B, Prieto J (2006). New therapies for hepatocellular carcinoma. Oncogene, 25, 3866-84. https://doi.org/10.1038/sj.onc.1209550
  4. Barazani Y, Hiatt JR, Tong MJ, Busuttil RW (2007). Chronic viral hepatitis and hepatocellular carcinoma. World J Surg, 31, 1243-8.
  5. Bashirova AA, Geijtenbeek TB, van Duijnhoven GC, et al (2001). A dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN)-related protein is highly expressed on human liver sinusoidal endothelial cells and promotes HIV-1 infection. J Exp Med, 193, 671-8. https://doi.org/10.1084/jem.193.6.671
  6. Befeler AS, Di Bisceglie AM (2002). Hepatocellular carcinoma: diagnosis and treatment. Gastroenterology, 122, 1609-19. https://doi.org/10.1053/gast.2002.33411
  7. Benjamini YH, Y (1995). Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J Royal Stat Society Series B (Methodological), 57, 289-300.
  8. Bieche I, Asselah T, Laurendeau I, et al (2005). Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology, 332, 130-44. https://doi.org/10.1016/j.virol.2004.11.009
  9. Block TM, Mehta AS, Fimmel CJ, Jordan R (2003). Molecular viral oncology of hepatocellular carcinoma. Oncogene, 22, 5093-107. https://doi.org/10.1038/sj.onc.1206557
  10. Bruix J, Sherman M, Llovet JM, et al (2001). Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol, 35, 421-30. https://doi.org/10.1016/S0168-8278(01)00130-1
  11. Capurro M, Wanless IR, Sherman M, et al (2003). Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology, 125, 89-97. https://doi.org/10.1016/S0016-5085(03)00689-9
  12. Chuma M, Sakamoto M, Yamazaki K, et al (2003). Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology, 37, 198-207. https://doi.org/10.1053/jhep.2003.50022
  13. Cocquerel L, Voisset C, Dubuisson J (2006). Hepatitis C virus entry: potential receptors and their biological functions. J Gen Virol, 87, 1075-84. https://doi.org/10.1099/vir.0.81646-0
  14. Cormier EG, Durso RJ, Tsamis F, et al (2004). L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc Natl Acad Sci U S A, 101, 14067-72. https://doi.org/10.1073/pnas.0405695101
  15. Degos F, Christidis C, Ganne-Carrie N, et al (2000). Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut, 47, 131-6. https://doi.org/10.1136/gut.47.1.131
  16. Donato F, Tagger A, Gelatti U, et al (2002). Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol, 155, 323-31. https://doi.org/10.1093/aje/155.4.323
  17. El-Serag HB, Hampel H, Javadi F (2006). The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol, 4, 369-80. https://doi.org/10.1016/j.cgh.2005.12.007
  18. Ferlay J, Shin HR, Bray F, et al (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer, 127, 2893-917. https://doi.org/10.1002/ijc.25516
  19. Gardner JP, Durso RJ, Arrigale RR, et al (2003). L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc Natl Acad Sci USA, 100, 4498-503. https://doi.org/10.1073/pnas.0831128100
  20. Gentleman RC, Carey VJ, Bates DM, et al (2004). Bioconductor: open software development for computational biology and bioinformatics. Genome Biol, 5, R80. https://doi.org/10.1186/gb-2004-5-10-r80
  21. Hochreiter S, Bodenhofer U, Heusel M, et al (2010). FABIA: factor analysis for bicluster acquisition. Bioinformatics, 26, 1520-7. https://doi.org/10.1093/bioinformatics/btq227
  22. Hui AM, Makuuchi M, Li X (1998). Cell cycle regulators and human hepatocarcinogenesis. Hepatogastroenterology, 45, 1635-42.
  23. Hulsegge I, Kommadath A, Smits MA (2009). Globaltest and GOEAST: two different approaches for Gene Ontology analysis. BMC Proc, 3 Suppl 4, S10.
  24. Jaskiewicz K, Chasen MR, Robson SC (1993). Differential expression of extracellular matrix proteins and integrins in hepatocellular carcinoma and chronic liver disease. Anticancer Res, 13, 2229-37.
  25. Kanehisa M (2002). The KEGG database. Novartis Found Symp, 247, 91-101; discussion -3, 19-28, 244-52.
  26. Koppel EA, van Gisbergen KP, Geijtenbeek TB, van Kooyk Y (2005). Distinct functions of DC-SIGN and its homologues L-SIGN (DC-SIGNR) and mSIGNR1 in pathogen recognition and immune regulation. Cell Microbiol, 7, 157-65.
  27. Kumar M, Sarin SK (2007). Is cirrhosis of the liver reversible? Indian J Pediatr, 74, 393-9. https://doi.org/10.1007/s12098-007-0067-1
  28. Levine AJ, Puzio-Kuter AM (2010). The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science, 330, 1340-4. https://doi.org/10.1126/science.1193494
  29. Li J, Tibshirani R (2011). Finding consistent patterns: A nonparametric approach for identifying differential expression in RNA-Seq data. Stat Methods Med Res.
  30. Lozach PY, Amara A, Bartosch B, et al (2004). C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. J Biol Chem, 279, 32035-45. https://doi.org/10.1074/jbc.M402296200
  31. Maere S, Heymans K, Kuiper M (2005). BiNGO: a Cytoscape plugin to assess overrepresentation of gene ontology categories in biological networks. Bioinformatics, 21, 3448-9. https://doi.org/10.1093/bioinformatics/bti551
  32. Marcellin P (1999). Hepatitis C: the clinical spectrum of the disease. J Hepatol, 31 Suppl 1, 9-16. https://doi.org/10.1016/S0168-8278(99)80368-7
  33. Marrero JA, Lok AS (2004). Newer markers for hepatocellular carcinoma. Gastroenterology, 127, S113-9. https://doi.org/10.1053/j.gastro.2004.09.024
  34. Seyer JM, Hutcheson ET, Kang AH (1977). Collagen polymorphism in normal and cirrhotic human liver. J Clin Invest, 59, 241-8. https://doi.org/10.1172/JCI108634
  35. Smith MW, Yue ZN, Geiss, et al (2003). Identification of novel tumor markers in hepatitis C virus-associated hepatocellular carcinoma. Cancer Res, 63, 859-64.
  36. Soini Y, Chia SC, Bennett WP, et al (1996). An aflatoxinassociated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis, 17, 1007-12. https://doi.org/10.1093/carcin/17.5.1007
  37. Swann JB, Smyth MJ (2007). Immune surveillance of tumors. J Clin Invest, 117, 1137-46. https://doi.org/10.1172/JCI31405
  38. Tai DI, Tsai SL, Chen YM, et al (2000). Activation of nuclear factor kappaB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. Hepatology, 31, 656-64. https://doi.org/10.1002/hep.510310316
  39. Thorgeirsson SS, Grisham JW (2002). Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet, 31, 339-46. https://doi.org/10.1038/ng0802-339
  40. Warburg O (1956). On the origin of cancer cells. Science, 123, 309-14. https://doi.org/10.1126/science.123.3191.309
  41. Wideroff L, Gridley G, Mellemkjaer L, et al (1997). Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst, 89, 1360-5. https://doi.org/10.1093/jnci/89.18.1360
  42. Wu ZL, Prather B, Ethen CM, et al (2011). Detection of specific glycosaminoglycans and glycan epitopes by in vitro sulfation using recombinant sulfotransferases. Glycobiology, 21, 625-33. https://doi.org/10.1093/glycob/cwq204
  43. Zhu N, Ware CF, Lai MM (2001). Hepatitis C virus core protein enhances FADD-mediated apoptosis and suppresses TRADD signaling of tumor necrosis factor receptor. Virology, 283, 178-87. https://doi.org/10.1006/viro.2001.0896

Cited by

  1. RETRACTED ARTICLE: Comparison of hepatocellular carcinoma (HCC), cholangiocarcinoma (CC), and combined HCC-CC (CHC) with each other based on microarray dataset vol.34, pp.3, 2013, https://doi.org/10.1007/s13277-013-0702-6
  2. IL28B rs12979860 Gene Polymorphism in Egyptian Patients with Chronic Liver Disease Infected with HCV vol.15, pp.17, 2014, https://doi.org/10.7314/APJCP.2014.15.17.7213
  3. Hepatitis C Virus Prevalence and Genotyping among Hepatocellular Carcinoma Patients in Baghdad vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7725
  4. Hepatitis C Virus (HCV) genotypes distribution among hepatocellular carcinoma patients in Southern Italy: a three year retrospective study vol.12, pp.1, 2017, https://doi.org/10.1186/s13027-017-0162-5